Answers are grounded in this paper and cite their sources.
Rhabdomyosarcomas (RMSs) represent more than 50% of soft tissue sarcomas occurring in childhood and adolescence. Although RMS is a rare tumor, it is one of the typical pediatric cancers. RMS is a highly malignant tumor that is characterized by local aggressiveness and a propensity to metastasize. Like other soft tissue sarcomas, an enlarging soft tissue mass is the usual expression of the primary tumor, but in deep sites (the pelvis, or trunk) the clinical evidence of the mass could appear relatively late. Ultrasonography is often the first diagnostic modality used in diagnosis. Computed tomography (CT) scans or magnetic resonance imaging (MRI) of the primary site improve the first local evaluation of the site and are mandatory for assessing local tumor extension before any treatment is given. After evidence of a suspected soft part lesion is obtained, pathological assessment is necessary to identify the histological nature of the tumor. In the past 30 years, the cure rate for RMS has dramatically improved from 25–30% (before the modern chemotherapy era) to approximately 70% This success is due to the development of multidisciplinary and risk-adapted treatment approaches developed by international cooperative groups. RMS is a rare tumor, and its treatment is necessarily multidisciplinary and complex. We analyse a clinical report of a child hospitalised in the ward of Pediatric Oncohematology of Policlinico San Matteo.
No takes yet. Share an insight, caveat, or question.
Burzio et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: